Drugs / AHN-12
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01207076 | Dec 2013 → Jul 2014 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00618696 | Jul 2005 → Dec 2007 | leukemia, myelodysplastic syndrome | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AHN-12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00618696 ↗ |
| Modality | Monoclonal antibody | “nonradiolabeled monoclonal antibody AHN-12” NCT00618696 ↗ |
| Route | Intravenous | “Patients receive nonradiolabeled monoclonal antibody AHN-12 IV” NCT00618696 ↗ |
| Target | PTPRC | “Leukocyte common antigen binding agent” CHEMBL2109480 ↗ |